The idea of model-based drug development championed by Lewis Sheiner, in which pharmacostatistical models of drug efficacy and safety are developed from preclinical and available clinical data, offers a quantitative approach to improving drug development and development decision-making. Examples are presented that support this paradigm. The first example describes a preclinical model of behavioral activity to predict potency and time-course of response in humans and assess the potential for differentiation between compounds. This example illustrates how modeling procedures expounded by Lewis Sheiner provided the means to differentiate potency and the lag time between drug exposure and response and allow for rapid decision making and dose selection. The second example involves planning a Phase 2a dose-ranging and proof of concept trial in Alzheimer’s disease (AD). The issue was how to proceed with the study and what criteria to use for a go/no go decision. The combined knowledge of AD disease progression, and preclinical and clinical information about the drug were used to simulate various clinical trial scenarios to identify an efficient and effective Phase 2 study. A design was selected and carried out resulting in a number of important learning experiences as well as extensive financial savings. The motivation for this case in point was the “Learn-Confirm” paradigm described by Lewis Sheiner. The final example describes the use of Pharmacokinetic and Pharmacodynamic (PK/PD) modeling and simulation to confirm efficacy across doses. In the New Drug Application for gabapentin, data from two adequate and well-controlled clinical trials was submitted to the Food and Drug Administration (FDA) in support of the approval of the indication for the treatment of post-herpetic neuralgia. The clinical trial data was not replicated for each of the sought dose levels in the drug application presenting a regulatory dilemma. Exposure response analysis submitted in the New Drug Application was applied to confirm the evidence of efficacy across these dose levels. Modeling and simulation analyses showed that the two studies corroborate each other with respect to the pain relief profiles. The use of PK/PD information confirmed evidence of efficacy across the three studied doses, eliminating the need for additional clinical trials and thus supporting the approval of the product. It can be speculated that the work by Lewis Sheiner reflected in the FDA document titled “Innovation or Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products” made this scientific approach to the drug approval process possible.
Article PDF
Similar content being viewed by others
Explore related subjects
Discover the latest articles, news and stories from top researchers in related subjects.Avoid common mistakes on your manuscript.
References
L.B. Sheiner (1997) ArticleTitleLearning versus confirming in clinical drug development Clin. Pharmacol. Ther. 61 275–291 Occurrence Handle10.1016/S0009-9236(97)90160-0 Occurrence Handle9084453 Occurrence Handle1:STN:280:ByiB3sfhtFM%3D
Food and Drug Administration. Innovation; Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products. www.fda.gov/oc/initiatives/criticalpath/whitepaper.html. 2004.
L.B. Sheiner D.R. Stanski S. Vozeh R.D. Miller (1979) ArticleTitleJ. Ham Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine Clin. Pharmacol. Ther. 25 358–371 Occurrence Handle761446 Occurrence Handle1:CAS:528:DyaE1MXhsl2qsro%3D
S.L. Beal L.B. Sheiner (1998) NONMEM Users Guide NONMEM project group University of California San Francisco
R. Miller J.D. Hermann W. Ewy K.G. Kowalski (2004) The strategic role and application of pharmacokinetic/pharmacodynamic modeling in drug development P.L. Bonate D.R Howard (Eds) Pharmacokinetics in Drug Development: Clinical Study Design and Analysis, Vol 1. AAPS Press Arlington VA 551–581
N.H.G. Holford K.E. Peace (1992a) ArticleTitleMethodologic aspects of a population pharmacodynamic model for cognitive effects in Alzheimer’s patients treated with tacrine Proc. Natl. Acad. Sci. USA. 89 11466–11470 Occurrence Handle1:CAS:528:DyaK3sXntlGgsQ%3D%3D
N.H.G. Holford K.E. Peace (1992b) ArticleTitleResults and validation of a population pharmacodynamic model for cognitive effects in Alzheimer’s patients treated with tacrine Proc. Natl. Acad. Sci. USA. 89 11471–11475 Occurrence Handle1:CAS:528:DyaK3sXntlGgtg%3D%3D
N.H.G. Holford K.E. Peace (1994) ArticleTitleThe effect of tacrine and lecithin in Alzheimer’s disease A population pharmacokinetic analysis of five clinical trials. Eur. J. Clin. Pharm. 47 17–23 Occurrence Handle1:STN:280:ByqD1c%2FjtF0%3D
Federal Food, Drug and Cosmetic Act of 1938, Drug Amendments of 1962. Pub. L. No. 87–781, 76 Stat. 780 (1962)
Food and Drug Administration Modernization Act of 1997, Pub. L. No. 105–115, 111 Stat. 2295 (1997).
Guidance for Industry: Exposure-response relationships, study design, data analysis and regulatory applications. Food and Drug Administration, May 2003, Guidance for Industry: Providing Clinical Evidence of Effectiveness for Human Drugs and Biological Products. Food and Drug Administration, May 1998.
B. Frame P. Burger R. Miller J. Cook E. Garafolo L. Knapp H.N. Bockbrader B.W. Corrigan (2001) An Analysis of Exposure Response data for Gabapentin for the Treatment of Neuropathic Pain Neuropathic Pain Meeting San Francsico
Neurontin® (Parke-Davis) Capsules. Physicians Desk Reference Electronic Library™ Online: ©2002. Thomson MICROMEDEX.
C.C. Peck D.B. Rubin L.B. Sheiner (2003) ArticleTitleHypothesis: A single clinical trial plus causal evidence of effectiveness is sufficient for drug approval Clin. Pharmacol. Ther. 73 481–490 Occurrence Handle10.1016/S0009-9236(03)00018-3 Occurrence Handle12811358
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Miller, R., Ewy, W., Corrigan, B.W. et al. How Modeling and Simulation Have Enhanced Decision Making in New Drug Development. J Pharmacokinet Pharmacodyn 32, 185–197 (2005). https://doi.org/10.1007/s10928-005-0074-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10928-005-0074-7